Clay Siegall, Seattle Genetics, & Cancer Research

Living in this modern society gives us many more advantages especially when it comes to innovation. Every era has it’s own innovative products, services, and individuals, but the 21st Century has taken it to another level. Cancer research is no different and the fight against cancer has become a hot topic as of late thanks to Clay Siegall. This individual is one of the most well respected individuals in this exclusive industry. Siegall is known by many as a scientist, doctor, investor, and philanthropist. His resume is very accomplished as well as he is the holder of 15 patents, has written 70 publications, and he’s won the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year Award.

Dr. Siegall is the CEO and President of Seattle Genetics. This biotech giant specializes in the development and commercialization of cancer breakthrough therapies. These are some of the finest cancer fighting drugs in history and Seattle Genetics produces them in abundance. It’s flagship drug ADCETRIS has racked up more than $350 Million. Thanks to Dr. Siegall’s business savvy approach, ADCETRIS was entered into multiple strategic licensing deals with Pfizer, Genentech, and GlaxoSmithKline. With this merger, ADCETRIS is now available for use in up to 65 countries worldwide. This Bothell, Washington based company is on a roll as it’s stock has tripled in only a five year span. Seattle Genetics has many more drugs in it’s advanced pipeline for future reference. Another hiring blitz s to be expected in the coming years, which will add to it’s already 800+ man roster.

Of course all of this wouldn’t be possible without Dr. Siegall. His broad educational background and strong passion have made the company into a high profile name. He’s been here since it’s inception back in 1998 as well. The future appears to be much more brighter with Dr. Siegall on the scene and Seattle Genetics will continue to rewrite history through cancer research.

 

Leave a Comment